Welcome to our dedicated page for Cvs Health SEC filings (Ticker: CVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CVS Health Corporation (NYSE: CVS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission (SEC). These filings document material events, financial results, capital markets transactions, governance changes and legal developments that affect CVS Health and its shareholders.
Among the key documents are current reports on Form 8-K, which CVS Health uses to announce items such as quarterly and year-to-date financial results, updated financial guidance, and Investor Day presentations. For example, the company has filed Form 8-K reports furnishing press releases that discuss strategic priorities, revenue and earnings guidance, and non-GAAP measures like adjusted operating income and adjusted earnings per share, along with reconciliations to GAAP metrics.
Other Form 8-K filings describe governance actions, including the Board of Directors’ appointment of J. David Joyner, President and Chief Executive Officer, to the additional role of Chair of the Board. Capital markets activity is also reflected in filings that detail the issuance of senior notes under an Underwriting Agreement, including principal amounts, maturities, interest rates and references to the governing senior indenture and registration statement.
Filings further address legal and subsidiary matters, such as the disclosure that Omnicare, LLC, a wholly owned indirect subsidiary of CVS Health, and certain of its subsidiary entities voluntarily initiated chapter 11 proceedings under the U.S. Bankruptcy Code to address litigation-related monetary damages and other financial challenges. These documents outline the use of debtor-in-possession financing and the evaluation of restructuring options.
On Stock Titan, AI-powered tools summarize and highlight the contents of CVS Health’s SEC filings, helping readers quickly identify key points in lengthy documents such as 8-Ks, and providing context around financial measures, governance changes and risk-related disclosures.
CVS Health (CVS) reported a routine equity compensation transaction for a director. On 11/20/2025, a CVS director received 1,775 shares of common stock at a price of $76.04 per share. The shares were issued as payment of a semi-annual retainer under CVS Health's 2017 Incentive Compensation Plan, rather than a cash payment.
Following this grant, the director beneficially owns 13,659 shares of CVS Health common stock in direct ownership. This filing reflects standard board compensation in stock and does not describe any broader corporate or strategic change at CVS Health.
CVS Health (CVS) director Fernando Aguirre reported the receipt of company stock as part of his regular board compensation. On 11/20/2025, he acquired 1,800 shares of CVS Health common stock at a price of $76.04 per share. This stock was issued as payment of a semi-annual retainer under the company’s 2017 Incentive Compensation Plan, meaning it represents routine director compensation rather than an open-market purchase. Following this grant, Aguirre beneficially owns 40,950 shares of CVS Health common stock, held directly.
CVS Health Corporation announced a governance change at the top of its leadership structure. On November 20, 2025, the Board appointed President and Chief Executive Officer J. David Joyner to also serve as Chair of the Board, effective January 1, 2026. After this change takes effect, Michael F. Mahoney will continue as Lead Independent Director, and Roger N. Farah, currently Executive Chair, will remain on the Board as a director. The company also issued a press release describing this appointment, which is filed as an exhibit.
CVS HEALTH Corp filed a Form 13F reporting institutional holdings. The filing lists a Form 13F Information Table Value Total of $102,889,417 across 3 holdings and shows 0 other included managers. The report was signed by Michael Motolo, Executive Director on 10-31-2025.
CVS Health (CVS) reported a Q3 2025 net loss driven by a non-cash impairment. Total revenues rose to $102.871B from $95.428B a year ago, led by higher product sales and premiums. However, a $5.725B goodwill impairment and higher operating costs pushed operating income to a loss of $3.207B versus income of $832M last year. Net loss attributable to CVS Health was $3.975B (diluted EPS -$3.13), compared with net income of $87M (EPS $0.07) in Q3 2024.
Year to date, revenues reached $296.374B, while net income attributable to CVS Health was a loss of $1.175B (EPS -$0.93). The quarter included a $483M gain on the deconsolidation of a subsidiary and $632M of net investment income. Cash from operations for the first nine months was $7.249B, essentially flat year over year. On the balance sheet, cash and cash equivalents were $9.098B, goodwill declined to $85.478B, and total debt (short-term, current portion of long-term, and long-term) remained significant. As of October 22, 2025, shares outstanding were 1,269,432,485.
CVS Health Corporation furnished an update on its financial performance. The company announced results for the three months ended September 30, 2025, and made the related press release available as Exhibit 99.1 under Item 2.02.
The materials are furnished, not filed, under the Exchange Act, which means they are not subject to Section 18 liability and are not incorporated by reference unless specifically stated.
CVS Health reported insider transactions by its EVP and Chief People Officer. The filing shows indirect purchases of common stock held by a trust for the benefit of the officer’s spouse. Reported trades: 35 shares at $56.47 on 09/09/2024, 10 shares at $62.24 on 10/02/2024, and 35 shares at $56.85 on 10/23/2024. The explanation notes the shares were bought at a broker’s discretion for a managed account and were not previously reported due to a broker error.
CVS Health Corp executive Heidi B. Capozzi filed an amended initial ownership report to include common stock held indirectly. The amendment reflects 5 shares of CVS common stock held by a trust for the benefit of her spouse, which had not been reported previously due to a broker error.
CVS Health Corporation reports that its wholly owned indirect subsidiary Omnicare, LLC and certain related entities have voluntarily begun chapter 11 bankruptcy proceedings in the U.S. to address issues arising from recent litigation in the U.S. District Court for the Southern District of New York, where the court imposed what Omnicare describes as excessive monetary damages.
Omnicare plans to use the court-supervised process to handle broader financial challenges in the long-term care pharmacy industry and to consider restructuring options, including a potential standalone restructuring or sale. Omnicare has arranged debtor-in-possession financing with a third party, which, once approved by the court and combined with ongoing operating cash flows, is expected to provide enough liquidity for the Omnicare entities to continue operating while the chapter 11 process proceeds.